Enzalutamide plus androgen-deprivation therapy in hormone-sensitive prostate cancer: new perspectives from a current Phase III clinical trial

Norz, Valentina; Lawaczeck, Laura; Bedke, Jens; Rausch, Steffen; Stenzl, Arnulf

dc.contributor.author	Norz, Valentina
dc.contributor.author	Lawaczeck, Laura
dc.contributor.author	Bedke, Jens
dc.contributor.author	Rausch, Steffen
dc.contributor.author	Stenzl, Arnulf
dc.date.accessioned	2020-12-28T08:18:05Z
dc.date.available	2020-12-28T08:18:05Z
dc.date.issued	2020
dc.identifier.issn	1744-8301
dc.identifier.uri	http://hdl.handle.net/10900/110932
dc.language.iso	en	de_DE
dc.publisher	Future Medicine Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.2217/fon-2019-0509	de_DE
dc.subject.ddc	610	de_DE
dc.title	Enzalutamide plus androgen-deprivation therapy in hormone-sensitive prostate cancer: new perspectives from a current Phase III clinical trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20200929220116_00698
utue.publikation.seiten	1511-1523	de_DE
utue.personen.roh	Norz, Valentina
utue.personen.roh	Lawaczeck, Laura
utue.personen.roh	Bedke, Jens
utue.personen.roh	Rausch, Steffen
utue.personen.roh	Stenzl, Arnulf
dcterms.isPartOf.ZSTitelID	Future Oncology	de_DE
dcterms.isPartOf.ZS-Issue	21	de_DE
dcterms.isPartOf.ZS-Volume	16	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE